BioMarin Pharma (BMRN) Tops Q2 EPS by 25c
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $60.26 -1.78%
Revenue Growth %: +31.4%
Financial Fact:
Selling, general and administrative: 118.76M
Today's EPS Names:
OCCI, IPX, ALZN, More
Revenue Growth %: +31.4%
Financial Fact:
Selling, general and administrative: 118.76M
Today's EPS Names:
OCCI, IPX, ALZN, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q2 EPS of $1.20, $0.25 better than the analyst estimate of $0.95. Revenue for the quarter came in at $990 million versus the consensus estimate of $939.37 million.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- OpenAI: after the Hugging Face incident, we committed to conducting a much broader review of actions taken by our models
- OpenAI says its agents leaked some user images - Reuters
- Nio and Geely Holding reach deal on battery swapping venture
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
